thermal cycler

Intas Science Imaging Instruments will launch the Dutch biotechnology company's NextGen PCR thermal cycler in the German market.

The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.

The exclusive deal includes sales and marketing of a rapid thermal cycler as well as consumable microplates and pipette tips. 

Dutch firm Molecular Biology Systems announced new distribution pacts for its ultra-fast thermal cycler in seven countries or regions.

Setup of the TTC.

The firm has improved design of the system for low-resource settings and validated it on clinical chlamydia samples and extracted HIV, Ebola, and dengue samples.

The company will showcase the next generation of its Philisa platform, a real-time PCR system which can run four multiplexed qPCR protocols in about 20 minutes.

A proof-of-principle study has shown a new qPCR device can detect bacterial DNA in under four minutes using droplet size as a readout of amplification.

The amplification method uses light-emitting diodes and gold foil to heat the reaction mixture and achieve 30 cycles in less than five minutes.

Anna-Sophia Boguraev during her visit to New England Biolabs. Credit: James McNeill

Co-sponsored by Boeing and miniPCR, the winning high school student's project will be carried out by astronauts aboard ISS and is believed to be the first ever PCR in space.

The Thermos thermal cycler.

The thermal cycler costs less than $130 to build using off-the-shelf supplies and boasts speeds of 17 seconds per cycle.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.